Shenzhen - Delayed Quote CNY

Sirio Pharma Co., Ltd. (300791.SZ)

Compare
22.13
-5.15
(-18.88%)
At close: 3:04:16 PM GMT+8
Loading Chart for 300791.SZ
  • Previous Close 27.28
  • Open 27.49
  • Bid 22.11 x --
  • Ask 22.18 x --
  • Day's Range 21.96 - 25.88
  • 52 Week Range 21.22 - 35.48
  • Volume 4,990,243
  • Avg. Volume 2,400,651
  • Market Cap (intraday) 5.251B
  • Beta (5Y Monthly) 0.87
  • PE Ratio (TTM) 14.66
  • EPS (TTM) 1.51
  • Earnings Date --
  • Forward Dividend & Yield 1.10 (4.03%)
  • Ex-Dividend Date Jun 21, 2024
  • 1y Target Est 30.11

Sirio Pharma Co., Ltd. operates as a contract manufacturer for dietary supplement industry worldwide. The company develops and manufactures a range of softgel dietary supplements; vegetarian softgel; nutraceutical gummies; probiotic products; tablet and powder products; capsules; and functional beverages. It also offers a range of services, including primary and final packaging. Sirio Pharma Co., Ltd. was founded in 1993 and is headquartered in Shantou, China.

www.siriopharma.com

2,610

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 300791.SZ

View More

Performance Overview: 300791.SZ

Trailing total returns as of 4/7/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

300791.SZ
15.95%
SSE Composite Index (000001.SS)
7.61%

1-Year Return

300791.SZ
18.70%
SSE Composite Index (000001.SS)
0.89%

3-Year Return

300791.SZ
9.81%
SSE Composite Index (000001.SS)
4.33%

5-Year Return

300791.SZ
32.44%
SSE Composite Index (000001.SS)
9.78%

Compare To: 300791.SZ

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 300791.SZ

View More

Valuation Measures

Annual
As of 4/3/2025
  • Market Cap

    6.47B

  • Enterprise Value

    7.35B

  • Trailing P/E

    18.08

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.55

  • Price/Book (mrq)

    2.67

  • Enterprise Value/Revenue

    1.78

  • Enterprise Value/EBITDA

    18.19

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    8.13%

  • Return on Assets (ttm)

    5.38%

  • Return on Equity (ttm)

    10.57%

  • Revenue (ttm)

    4.13B

  • Net Income Avi to Common (ttm)

    335.69M

  • Diluted EPS (ttm)

    1.51

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    637.4M

  • Total Debt/Equity (mrq)

    58.67%

  • Levered Free Cash Flow (ttm)

    -70.78M

Research Analysis: 300791.SZ

View More

Company Insights: 300791.SZ

Research Reports: 300791.SZ

View More

People Also Watch